NEW YORK (360Dx) – Clinical Genomics and Quest Diagnostics today announced the US Food and Drug Administration cleared InSure One, a fecal immunochemical test, or FIT, designed to detect blood in stool.

Clinical Genomics manufactures InSure FIT tests, including InSure One, which Quest provides to physicians and organized provider groups, including through specialized programs with accountable care organizations across the US. The companies expect the test to be commercially available in early 2018.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Feb
22
Sponsored by
SeraCare

This webinar will walk through key considerations and helpful guidelines to accelerate next-generation sequencing (NGS)-based clinical genomics assay validation for less money and greater confidence in results.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.